1611 related articles for article (PubMed ID: 11902303)
21. Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
Chen YC; Ho CL; Kao WY; Hwang JM; Sheu LF; Chao TY
Ann Hematol; 2001 Nov; 80(11):647-52. PubMed ID: 11757723
[TBL] [Abstract][Full Text] [Related]
22. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
23. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
24. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
Yetgin S; Cetin M
Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
[TBL] [Abstract][Full Text] [Related]
25. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
26. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Henze G; v Stackelberg A; Eckert C
Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
[TBL] [Abstract][Full Text] [Related]
27. Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
Mantadakis E; Smith AK; Hynan L; Winick NJ; Kamen BA
J Pediatr Hematol Oncol; 2002 Nov; 24(8):636-42. PubMed ID: 12439035
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
29. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
30. Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
Tutor O; Díaz MA; Ramírez M; Algara P; Madero L; Martínez P
Leuk Res; 2002 Sep; 26(9):817-20. PubMed ID: 12127556
[TBL] [Abstract][Full Text] [Related]
31. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
32. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90.
Neth O; Seidemann K; Jansen P; Mann G; Tiemann M; Ludwig WD; Riehm H; Reiter A
Med Pediatr Oncol; 2000 Jul; 35(1):20-7. PubMed ID: 10881003
[TBL] [Abstract][Full Text] [Related]
33. [Results and experiences with a modified BFM protocol for treatment of recurrences in children with acute lymphoblastic leukemia in East German areas].
Sauerbrey A; Zintl F; Malke H; Reimann M; Maaser M; Domula M; Dörffel W; Eggers G; Exadaktylos P; Kotte W
Klin Padiatr; 1993; 205(4):281-7. PubMed ID: 8377448
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.
Matsuzaki A; Ishii E; Nagatoshi Y; Eguchi H; Koga H; Yanai F; Inada H; Nibu K; Tamai Y; Akiyoshi K; Nakayama H; Hara T; Take H; Miyazaki S; Okamura J
Int J Hematol; 2001 Apr; 73(3):369-77. PubMed ID: 11345205
[TBL] [Abstract][Full Text] [Related]
35. Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
Grenzebach J; Schrappe M; Ludwig WD; Parwaresch R; Zimmermann M; Gadner H; Riehm H; Reiter A;
Ann Hematol; 2001; 80 Suppl 3():B73-6. PubMed ID: 11757713
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
Sun XF; Jiang WQ; Liu DG; Xia ZJ; Huang HQ; Zhang L; Li YH; Zhou ZM; Zhen ZJ; Xia Y; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1687-91. PubMed ID: 15601561
[TBL] [Abstract][Full Text] [Related]
37. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group.
Steinherz PG; Gaynon P; Miller DR; Reaman G; Bleyer A; Finklestein J; Evans RG; Meyers P; Steinherz LJ; Sather H
J Clin Oncol; 1986 May; 4(5):744-52. PubMed ID: 3517244
[TBL] [Abstract][Full Text] [Related]
38. High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Mottl H; Bajciova V; Nemec J; Al Shemmari S; Al Awadi S
Pediatr Hematol Oncol; 2003 Mar; 20(2):103-10. PubMed ID: 12554521
[TBL] [Abstract][Full Text] [Related]
39. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
[TBL] [Abstract][Full Text] [Related]
40. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
